Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
GLP-1 lowers blood glucose in fasting type 2 diabetic patients. To clarify the relation of the effect of GLP-1 to obesity, blood glucose, beta-cell function, and insulin sensitivity, GLP-1 (1.2 pmol/kg.min) was infused iv for 4-6 h into 50 fasting type 2 diabetic patients with a wide range of age, body mass index, HbA1c, and fasting plasma glucose. The effectiveness of GLP-1 was evaluated by calculation of a glucose disappearance constant for each individual (Kg, linear slope of log-transformed plasma glucose), and by the lowest stable glucose level (Nadir plasma glucose) obtained during the infusion. Grouped according to fasting plasma glucose (<10, 10-15, >15 mmol/liter), Kg values were 0.45 +/- 0.03, 0.38 +/- 0.04, and 0.28 +/- 0.04%/min (P = 0.005), and Nadir plasma glucose values were 4.7 +/- 0.1 (3.9-5.9), 5.8 +/- 0.4 (4.3-8.4), and 8.7 +/- 1.4 (6.2-18.7) mmol/liter (P = 0.0003). Nonresponders were not identified. Multiple regression analysis with Kg or Nadir plasma glucose as the dependent parameter and body mass index, age, gender, diabetes duration, and significantly correlated parameters (in multiple regression for Kg: fasting plasma glucose, fasting nonesterified fatty acid, dipeptidyl peptidase activity, peak insulin, and the logarithm of beta-cell function; and for Nadir plasma glucose: fasting plasma glucose, fasting nonesterified fatty acid, dipeptidyl peptidase activity, delta glucagon decrement, F-GLP-1 total, logarithm of beta-cell function, and Kg) as independent parameters resulted in fasting plasma glucose as the only significant predictor of Kg, and fasting plasma glucose and Kg as predictors of Nadir plasma glucose. Kg and Nadir plasma glucose were neither influenced by treatment nor by neuropathy per se. In conclusion, GLP-1 lowers plasma glucose in type 2 diabetes regardless of severity, but glucose elimination is faster and obtained glycemic level lower in patients with the lower fasting plasma glucose. Not all patients can be expected to reach normoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [7]
Citations
Cites
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Levy, J. C., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,013
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“HE INCRETIN HORMONE GLP-1 stimulates glucoseinduced insulin secretion and inhibits glucagon secretion (1, 2). As a result of these actions, hepatic glucose production and blood glucose concentrations decrease (3, 4). The ability of GLP-1 to modulate insulin and glucagon secretion is preserved in type 2 diabetic patien…”
BackgroundSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“In nonfasting patients an inhibitory effect on gastric emptying rate adds to the glucose-lowering effect by delaying glucose entry and uptake from the intestine (10, 11 ).”
BackgroundSelf-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“From the discovery of the GLP-1 fragment GLP-1(7-37) to the development of more stable and long-acting GLP-1 analogs, these milestones represent signi fi cant breakthroughs in the medical fi eld.”
BackgroundSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“Against this background, reports that GLP-1 secretion from L-cells is reduced in patients with type 2 diabetes [10, 11] have prompted several hypotheses about how this affects the estimated clinical effectiveness of these novel drugs.”
BackgroundSelf-citationCardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Maggio, C. A., & Pi-Sunyer, F. X. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00071-9 · Cited by 351
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Self-citationVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“A notable exception were patients with fasting glucose concentrations >250 mg/dL [213], in whom the duration of the experiments probably was too short to reach a full normalization.”
BackgroundResultAnti-diabetic drugs recent approaches and advancements
Dowarah, J., & Singh, V. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115263 · Cited by 227
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
“In randomized order, intravenous infusions of GLP-1(7-36)-amide (1.”
BackgroundSelf-citationVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Wewer Albrechtsen, N. J., Hartmann, B., Veedfald, S., Windeløv, J. A., Plamboeck, A., Bojsen-Møller, K. N., Idorn, T., Feldt-Rasmussen, B., Knop, F. K., Vilsbøll, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3283-z · Cited by 185
Self-citationGlucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
Self-citationCoffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators
Tunnicliffe, J. M., & Shearer, J. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-123 · Cited by 167
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
Al-masri, I. M., Mohammad, M. K., & Tahaa, M. O. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360802610761 · Cited by 159
The Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
Self-citationBak, M. J., Albrechtsen, N. W., Pedersen, J., Hartmann, B., Christensen, M., Vilsbøll, T., Knop, F. K., Deacon, C. F., Dragsted, L. O., & Holst, J. J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0941 · Cited by 136
Self-citationHolz, G., & Chepurny, O. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 131
Bala, V., Rajagopal, S., Kumar, D. P., Nalli, A. D., Mahavadi, S., Sanyal, A. J., Grider, J. R., & Murthy, K. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00420 · Cited by 123
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
Foley (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10952 · Cited by 119
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 118
Knop, F. K., Vilsbøll, T., Larsen, S., Højberg, P. V., Vølund, A., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00059.2006 · Cited by 120
Self-citationThe Incretin Approach for Diabetes Treatment
Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 106
Self-citationQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Charoenkwan, P., Kanthawong, S., Nantasenamat, C., Hasan, M. M., & Shoombuatong, W. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00590 · Cited by 111
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
Meneilly, G. S., Greig, N., Tildesley, H., Habener, J. F., Egan, J. M., & Elahi, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2835 · Cited by 99
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 100
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
Lenhard, J. M., Croom, D. K., & Minnick, D. T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.021 · Cited by 96
Incretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease
Skov, J., Persson, F., Frøkiær, J., & Christiansen, J. S. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00023 · Cited by 91
Diabetes-related alterations in the enteric nervous system and its microenvironment
Bagyánszki, M. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i5.80 · Cited by 71
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Sonne, D. P., Hansen, M., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0154 · Cited by 75
Dysglycaemia in the critically ill – significance and management
Deane, A. M., & Horowitz, M. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12078 · Cited by 81
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 80
Myint, K. S., Greenfield, J. R., Farooqi, I. S., Henning, E., Holst, J. J., & Finer, N. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1065 · Cited by 77
Self-citationHolst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationEmerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
The Role of cAMP in Beta Cell Stimulus–Secretion and Intercellular Coupling
Stožer, A., Leitgeb, E. P., Pohorec, V., Dolenšek, J., Bombek, L. K., Gosak, M., & Klemen, M. S. (2021) · Cells · doi:10.3390/cells10071658 · Cited by 75
Microbial Regulation of Glucose Metabolism and Insulin Resistance
Crommen, S., & Simon, M.-C. (2017) · Genes · doi:10.3390/genes9010010 · Cited by 65
Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents
Christiansen, C. B., Trammell, S. A. J., Wewer Albrechtsen, N. J., Schoonjans, K., Albrechtsen, R., Gillum, M. P., Kuhre, R. E., & Holst, J. J. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00010.2019 · Cited by 67
Self-citationSonne, D. P., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0309 · Cited by 65
Self-citationShamekhi, F., Tamjid, E., & Khajeh, K. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.08.078 · Cited by 70
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
Suh, H.-W., Lee, K.-B., Kim, K., Yang, H. J., Choi, E., Shin, M. H., Park, Y. S., Na, Y., Ahn, K. S., Jang, Y. P., et al. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.06.042 · Cited by 65
Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients
Sonne, D. P., Hare, K. J., Martens, P. C., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00435.2012 · Cited by 64
Self-citationExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“Treatment with exogenous GLP-1 improves glycaemic control in patients with Type 2 diabetes [12].”
BackgroundPalladino, A. A., Sayed, S., Levitt Katz, L. E., Gallagher, P. R., & De León, D. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1263 · Cited by 61
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., & Tanaka, I. (2003) · Metabolism · doi:10.1053/meta.2003.50014 · Cited by 59
The TRPA1 Agonist, Methyl Syringate Suppresses Food Intake and Gastric Emptying
Kim, M. J., Son, H. J., Song, S. H., Jung, M., Kim, Y., & Rhyu, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071603 · Cited by 58
Lee, H. M., Joo, B. S., Lee, C. H., Kim, H. Y., Ock, J. H., & Lee, Y. S. (2015) · Journal of Menopausal Medicine · doi:10.6118/jmm.2015.21.2.93 · Cited by 58
Argyrakopoulou, G., Simati, S., Dimitriadis, G., & Kokkinos, A. D. (2020) · Nutrients · doi:10.3390/nu12061734 · Cited by 58
The management of the obese diabetic patient
Albu, J., & Raja-Khan, N. T. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00043-5 · Cited by 58
Vilarrasa, N., de Gordejuela, A. G. R., Casajoana, A., Duran, X., Toro, S., Espinet, E., Neto, M. G., Vendrell, J. J., López‐Urdiales, R., Pérez, M., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2311-0 · Cited by 51
Cuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.001 · Cited by 51
Ullrich, S. S., Fitzgerald, P. C. E., Schober, G., Steinert, R. E., Horowitz, M., & Feinle‐Bisset, C. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.140640 · Cited by 48
New directions for protease inhibitors directed drug discovery
Hamada, Y., & Kiso, Y. (2015) · Biopolymers · doi:10.1002/bip.22780 · Cited by 44
The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
Gilor, C., Graves, T. K., Gilor, S., Ridge, T. K., & Rick, M. (2011) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2011.03.001 · Cited by 44
Bhat, G. A., Khan, H. A., Alhomida, A. S., Sharma, P. K., Singh, R., & Paray, B. A. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2227-4 · Cited by 38
Nauck, M. A., Baranov, O., Ritzel, R. A., & Meier, J. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2953-6 · Cited by 37
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 36
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00103.x · Cited by 35
A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
Munaf, M., Pellicori, P., Allgar, V., & Wong, K. (2012) · International Journal of Peptides · doi:10.1155/2012/249827 · Cited by 30
Vahl, T. P., & D’Alessio, D. A. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000078991.96795.84 · Cited by 33
Kishimoto, M., & Noda, M. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-115 · Cited by 32
Skovgaard, M., Kodra, J. T., Gram, D. X., Knudsen, S. M., Madsen, D., & Liberles, D. A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.08.066 · Cited by 32
Hussein, M. S., Abushady, M. M., Refaat, S., & Ibrahim, R. Y. M. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.10.012 · Cited by 31
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
Kennedy, L., & Peters, A. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.04 · Cited by 31
2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV
Haffner, C. D., McDougald, D. L., Reister, S. M., Thompson, B. D., Conlee, C., Fang, J., Bass, J. Y., Lenhard, J. M., Croom, D. K., Secosky-Chang, M. B., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.050 · Cited by 30
Tang, J., Pei, Y., & Zhou, G. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.04.013 · Cited by 28
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Hansen, C. F., Vassiliadis, E., Vrang, N., Sangild, P. T., Cummings, B. P., Havel, P. J., & Jelsing, J. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.01.002 · Cited by 26
Deng, X., Shen, J., Zhu, H., Xiao, J., Sun, R., Xie, F., Lam, C., Wang, J., Qiao, Y., Tavallaie, M. S., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.006 · Cited by 26
Ballav, C., & Gough, S. C. L. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7314 · Cited by 24
Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 24
Watkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 23
Self-citationRedij, T., Chaudhari, R. R., Li, Z., Hua, X., & Li, Z. (2019) · ACS Omega · doi:10.1021/acsomega.8b03052 · Cited by 23
Trahair, L. G., Horowitz, M., Marathe, C. S., Lange, K., Standfield, S., Rayner, C. K., & Jones, K. L. (2014) · Physiological Reports · doi:10.14814/phy2.12204 · Cited by 22
Gastrointestinal motility in patients with end‐stage renal disease on chronic hemodialysis
Broberg, B., Madsen, J. L., Fuglsang, S., Holst, J. J., Christensen, K. B., Rydahl, C., Idorn, T., Feldt‐Rasmussen, B., & Hornum, M. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13554 · Cited by 21
Self-citationJiang, T., Zhou, Y., Chen, Z., Sun, P. G., Zhu, J., Zhang, Q., Wang, Z., Shao, Q., Jiang, X., Li, B., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00074 · Cited by 21
The metabolic syndrome influences the response to incretin-based therapies
Fadini, G. P., de Kreutzenberg, S. V., Gjini, R., & Avogaro, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0296-7 · Cited by 20
Role of Surgery in Management of Type 2 Diabetes Mellitus
Herron, D. M., & Tong, W. W. Y. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20114 · Cited by 20
Hibi, M., Hari, S., Yamaguchi, T. F., Mitsui, Y., Kondo, S., & Katashima, M. (2019) · Nutrients · doi:10.3390/nu11092126 · Cited by 18
Reebye, V., Sætrom, P., Mintz, P. J., Rossi, J. J., Kasahara, N., Nteliopoulos, G., Nicholls, J. P., Haoudi, A., Gordon, M. Y., & Habib, N. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.23 · Cited by 18
Pang, B., Kim, S. J., Li, D., Ma, Z., Sun, B., Zhang, X., Wu, Z., & Chen, L. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5136 · Cited by 16
Shin, M.-H., Suh, H.-W., Lee, K.-B., Kim, K., Yang, H. J., Choi, E., Cho, Y. J., Song, M., Ahn, K. S., & Jang, H.-J. (2012) · BioChip Journal · doi:10.1007/s13206-012-6202-8 · Cited by 16
Metadata
- Authors
- Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-08
- Volume
- 86
- Issue
- 8
- Pages
- 3853-3860
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2056934377
- Cited by
- 164
- References
- 24
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 5 · 2016: 8 · 2015: 9 · 2014: 14 · 2013: 16 · 2012: 9
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Hvidovre Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, fasting blood glucose, glucose disappearance rate, beta-cell function, insulin sensitivity, glucagon, obesity, neuropathy
- MeSH terms
- Autoantibodies, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Fasting, Fatty Acids, Nonesterified, Female, Glucagon, Glutamate Decarboxylase, Glycated Hemoglobin, Humans, Infusions, Intravenous, Insulin, Islets of Langerhans, Isoenzymes, Male, Middle Aged, Peptide Fragments, Protein Precursors, Regression Analysis, Body Mass Index, Dipeptidyl Peptidase 4, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.